SEC Form 4 · accession 0000899243-17-018364
SOLENO THERAPEUTICS INC · SLNO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James Walter Glasheen
Director · 10% Owner
Period of report
Jul 6, 2017
Accepted (ET)
Jul 17, 2017 · 8:55 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001484565
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jul 6, 2017 | A | 11,213 | $0.61 | A | 13,791 | D | |
| Common StockF3 | holding | — | — | — | 7,050,691 | I | See footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Effective January 1, 2017, annual board and committee retainers payable to directors will be made in equivalent shares of the Issuer's common stock, on a quarterly basis.
- F2The number of shares issuable in lieu of cash retainers was determined using the closing price per share of Issuer common stock on July 6, 2017, or $0.61.
- F3Consists of shares held by Technology Partners Fund VII, L.P and Tehnology Partners Affiliates VII, L.P. or Technology Affiliates. James Glasheen is one of the managing members of Technology Partners and Technology Affiliates and has shared voting power over the shares of common stock beneficially owned by Technology Partners and Technology Affiliates. M r. Glasheen disclaims beneficial ownership of such securities, except to the extent, if any, of his pecuniary interest therein.